- Initial Statement of Beneficial Ownership (3)
06 Dezember 2012 - 6:20PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Pollack Kevin
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/17/2012
|
3. Issuer Name
and
Ticker or Trading Symbol
Lightlake Therapeutics Inc. [LLTP]
|
(Last)
(First)
(Middle)
86 GLOUCESTER PLACE, GROUND FLOOR SUITE
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__
X
__ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
Chief Financial Officer /
|
(Street)
LONDON, ENGLAND W1U 6HP
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Options
(1)
|
4/17/2012
(1)
|
1/16/2020
(1)
|
Common Stock
|
2000000
|
$0.10
|
D
|
|
Options
|
11/26/2012
|
11/25/2022
|
Common Stock
|
1250000
|
$0.12
|
D
|
|
Options
(2)
|
11/26/2012
(2)
|
8/25/2023
(2)
|
Common Stock
|
2250000
|
$0.12
|
D
|
|
Explanation of Responses:
|
(
1)
|
250,000 vest on 4/17/12, 250,000 vest on 7/17/12, 250,000 vest on 10/17/12, 250,000 vest on 1/17/13, 125,000 vest on 4/17/13, 125,000 vest on 7/17/13, 125,000 vest on 10/17/13, 125,000 vest on 1/17/14, 125,000 vest on 4/17/14, 125,000 vest on 7/17/14, 125,000 vest on 10/17/14, and 125,000 vest on 1/17/15. All expire 5 years after their respective vesting dates.
|
(
2)
|
562,500 vest on 11/26/12, 562,500 vest on 2/26/13, 562,500 vest on 5/26/13, and 562,500 vest on 8/26/13. All expire 10 years after their respective vesting dates.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Pollack Kevin
86 GLOUCESTER PLACE
GROUND FLOOR SUITE
LONDON, ENGLAND W1U 6HP
|
X
|
|
Chief Financial Officer
|
|
Signatures
|
/s/Kevin Pollack
|
|
12/5/2012
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Opiant Pharmaceuticals Inc (NASDAQ): 0 Nachrichtenartikel
Weitere Lightlake Therapeutics (QB) News-Artikel